3Screen™ - Assay development services based on cleared-tissue image analysis

Healthy mammary tissue.png

1. Define Scope

What is the problem and what are the endpoints?

Customized assay endpoints based on tissue clearing. 
Let us help you get the most out of your tissues.

With our extensive portfolio of over 50   High Content Screening assays enhanced by tissue clearing, we are able to tailor any assay to meet your needs. 

Projections of DUP_1A0000.jpg

Microtissue DILI screening

Evaluate drug induced liver injury in microtissue models

Visikol-proliferation spheroid.png

Antiproliferative drug microtissue screening

Call now to discuss your project with our scientists

1-800-615-VISI (8474)
Ext 100

Get a Quote Today

Name *

Leveraging our expertise in whole-mount immunolabeling, we can convert any traditional cell-based assay, microtissue assay, or IHC endpoint into a high-content imaging workflow. 

Tired of slides?  We employ whole-mount immunolabeling and tissue clearing to convert IHC to HCS.

  • Antibody penetration
  • Apoptosis
  • Angiogenesis
  • Cell-cell junctions and cadherins
  • Cell proliferation
  • Cell migration
  • Cell viability
  • Cholestasis
  • Drug induced liver injury
  • Fibrosis
  • Immune cell invasion
  • Inflammatory Signaling
  • Mitochondrial Health + Toxicity
  • NASH
  • Neuronal Differentiation
  • Neuronal Function
  • ROS
  • Steatosis

Visikol-mammary tumor ki67.png

2. Pilot Project

We work with you to develop proof of concept for desired endpoints

Typically 2-3 week turnaround on pilot projects. We optimize methodology customized to your requirements and imaging capabilities.

3.  Implementation

Visikol will develop the assay as a custom service to suit your needs or for implementation into your lab